Alzheimer; News from the web:

Alzamend Neuro has dosed the first patient in the multiple ascending dose portion of its Phase 2a clinical trial of AL001, an investigational oral therapy for dementia related to Alzheimer’s disease.

This multiple ascending dose (MAD) part follows positive results from a Phase 1 trial. Topline data from the Phase 2a trial is expected in December.

Read all about it HERE